263 related articles for article (PubMed ID: 33733587)
21. SLC13A4 Might Serve as a Prognostic Biomarker and be Correlated with Immune Infiltration into Head and Neck Squamous Cell Carcinoma.
Yang ML; Zhang JH; Li S; Zhu R; Wang L
Pathol Oncol Res; 2021; 27():1609967. PubMed ID: 34840533
[TBL] [Abstract][Full Text] [Related]
22. Upregulation of secreted phosphoprotein 1 affects malignant progression, prognosis, and resistance to cetuximab via the KRAS/MEK pathway in head and neck cancer.
Liu K; Hu H; Jiang H; Liu C; Zhang H; Gong S; Wei D; Yu Z
Mol Carcinog; 2020 Oct; 59(10):1147-1158. PubMed ID: 32805066
[TBL] [Abstract][Full Text] [Related]
23. Identification of Immune Subtypes for Predicting the Prognosis of Patients in Head and Neck Squamous Cell Carcinoma.
Sun J; Fang G; Zuo Z; Yu X; Xue L; Li C; Li S
Technol Cancer Res Treat; 2021; 20():15330338211045823. PubMed ID: 34657509
[TBL] [Abstract][Full Text] [Related]
24. Prognostic role of DFNA5 in head and neck squamous cell carcinoma revealed by systematic expression analysis.
Liu Z; Liu H; Dong Q; Li H; Zhang B; Liu Y; Zhong L; Tang H
BMC Cancer; 2021 Aug; 21(1):951. PubMed ID: 34433433
[TBL] [Abstract][Full Text] [Related]
25. The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab
Baysal H; De Pauw I; Zaryouh H; Peeters M; Vermorken JB; Lardon F; De Waele J; Wouters A
Front Immunol; 2021; 12():737311. PubMed ID: 34557197
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of BASP1 Indicates a Poor Prognosis in Head and Neck Squamous Cell Carcinoma.
Jaikumarr Ram A; Girija As S; Jayaseelan VP; Arumugam P
Asian Pac J Cancer Prev; 2020 Nov; 21(11):3435-3439. PubMed ID: 33247706
[TBL] [Abstract][Full Text] [Related]
27. Targeting resistance to radiation-immunotherapy in cold HNSCCs by modulating the Treg-dendritic cell axis.
Knitz MW; Bickett TE; Darragh LB; Oweida AJ; Bhatia S; Van Court B; Bhuvane S; Piper M; Gadwa J; Mueller AC; Nguyen D; Nangia V; Osborne DG; Bai X; Ferrara SE; Boss MK; Goodspeed A; Burchill MA; Tamburini BAJ; Chan ED; Pickering CR; Clambey ET; Karam SD
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33883256
[TBL] [Abstract][Full Text] [Related]
28. Impaired intratumoral natural killer cell function in head and neck carcinoma.
Mele D; Pessino G; Trisolini G; Luchena A; Benazzo M; Morbini P; Mantovani S; Oliviero B; Mondelli MU; Varchetta S
Front Immunol; 2022; 13():997806. PubMed ID: 36341402
[TBL] [Abstract][Full Text] [Related]
29. Identification of Tumor Suppressive Genes Regulated by
Oshima S; Asai S; Seki N; Minemura C; Kinoshita T; Goto Y; Kikkawa N; Moriya S; Kasamatsu A; Hanazawa T; Uzawa K
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34201353
[TBL] [Abstract][Full Text] [Related]
30. Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma.
Zhang PF; Gao C; Huang XY; Lu JC; Guo XJ; Shi GM; Cai JB; Ke AW
Mol Cancer; 2020 Jun; 19(1):110. PubMed ID: 32593303
[TBL] [Abstract][Full Text] [Related]
31. ETV5 facilitates tumor progression in head-neck squamous cell carcinoma.
Yu S; Ma Z; Chen T; Wang H; Yao Q; Li J; Cheng J
Oral Dis; 2024 May; 30(4):2004-2017. PubMed ID: 37649213
[TBL] [Abstract][Full Text] [Related]
32. Slug is a novel molecular target for head and neck squamous cell carcinoma stem-like cells.
Moon JH; Lee SH; Koo BS; Kim JM; Huang S; Cho JH; Eun YG; Shin HA; Lim YC
Oral Oncol; 2020 Dec; 111():104948. PubMed ID: 32771963
[TBL] [Abstract][Full Text] [Related]
33. m7G-related genes-NCBP2 and EIF4E3 determine immune contexture in head and neck squamous cell carcinoma by regulating CCL4/CCL5 expression.
Xu X; Zhao Y; Ying Y; Zhu H; Luo J; Mou T; Zhang Z
Mol Carcinog; 2023 Aug; 62(8):1091-1106. PubMed ID: 37067401
[TBL] [Abstract][Full Text] [Related]
34. Metabolic landscape of head and neck squamous cell carcinoma informs a novel kynurenine/Siglec-15 axis in immune escape.
Zhang XY; Shi JB; Jin SF; Wang RJ; Li MY; Zhang ZY; Yang X; Ma HL
Cancer Commun (Lond); 2024 Jun; 44(6):670-694. PubMed ID: 38734931
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma.
Zhang J; Zhong X; Jiang H; Jiang H; Xie T; Tian Y; Li R; Wang B; Zhang J; Yuan Y
Aging (Albany NY); 2020 Nov; 12(22):22509-22526. PubMed ID: 33216727
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive review regarding the association of E2Fs with the prognosis and immune infiltrates in human head and neck squamous cell carcinoma.
Du W; Xia X; Gou Q; Xie Y; Gao L
Asian J Surg; 2024 May; 47(5):2106-2121. PubMed ID: 38320907
[TBL] [Abstract][Full Text] [Related]
37. Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma.
Xu X; Li R; Zhang L; Zhu G; Ren D; Wu L; Gong X
Diagn Pathol; 2021 Nov; 16(1):110. PubMed ID: 34823553
[TBL] [Abstract][Full Text] [Related]
38. c-MYC-directed NRF2 drives malignant progression of head and neck cancer via glucose-6-phosphate dehydrogenase and transketolase activation.
Tang YC; Hsiao JR; Jiang SS; Chang JY; Chu PY; Liu KJ; Fang HL; Lin LM; Chen HH; Huang YW; Chen YT; Tsai FY; Lin SF; Chuang YJ; Kuo CC
Theranostics; 2021; 11(11):5232-5247. PubMed ID: 33859744
[No Abstract] [Full Text] [Related]
39. CHMP2A regulates tumor sensitivity to natural killer cell-mediated cytotoxicity.
Bernareggi D; Xie Q; Prager BC; Yun J; Cruz LS; Pham TV; Kim W; Lee X; Coffey M; Zalfa C; Azmoon P; Zhu H; Tamayo P; Rich JN; Kaufman DS
Nat Commun; 2022 Apr; 13(1):1899. PubMed ID: 35393416
[TBL] [Abstract][Full Text] [Related]
40. Combined IL6 and CCR2 blockade potentiates antitumor activity of NK cells in HPV-negative head and neck cancer.
Yang F; Yuan C; Chen F; Qin ZS; Schmitt NC; Lesinski GB; Saba NF; Teng Y
J Exp Clin Cancer Res; 2024 Mar; 43(1):76. PubMed ID: 38468260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
